We just partnered with one of the hottest biotech's around at the moment that is growing its Clin Ops team ahead of a large phase 3 Oncology trial.
This company is founded and led by some of the industries brightest with their C suite coming from the likes of Merck. Much of their leadership were crucial to the development of Keytruda. This company is one that has potential well beyond just one blockbuster drug due to their proprietary drug discovery platform. This platform is rooted in a new way to characterize protein that has led them to much more accurate drug targets. What makes this exciting is that it not only has applications in Oncology, but Neurology and Immunology as well.
With nearly $800 million in funding they have a cash runway for years to come, and their current pipeline is robust. In addition to the phase 3 you will be working on they have 11 other indication in development.
